Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
4 African trypanosomiasis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
5 African trypanosomiasis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
6 African trypanosomiasis 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
7 African trypanosomiasis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
8 African trypanosomiasis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
14 Alcoholic liver disease 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
15 Alcoholic liver disease 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
16 Alcoholic liver disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
17 Alcoholic liver disease 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
18 Alcoholic liver disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
19 Alcoholic liver disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
20 Allograft rejection 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
21 Allograft rejection 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
22 Allograft rejection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
23 Allograft rejection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
24 Alzheimer disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
25 Alzheimer disease 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
26 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
27 Alzheimer disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
28 Alzheimer disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
29 Amoebiasis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
30 Amoebiasis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
31 Amoebiasis 💬
 2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
32 Amoebiasis 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
33 Amoebiasis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
34 Amoebiasis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
35 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
36 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
37 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
38 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
39 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
40 Antifolate resistance 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
41 Antifolate resistance 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
42 Antifolate resistance 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
43 Antifolate resistance 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
44 Antigen processing and presentation 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
45 Antigen processing and presentation 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
46 Apoptosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
47 Apoptosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
48 Asthma 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
49 Asthma 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
50 Autoimmune thyroid disease 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
51 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
52 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
53 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
54 C-type lectin receptor signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
55 C-type lectin receptor signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
56 C-type lectin receptor signaling pathway 💬
 1件: IL23A 💬 Guselkumab 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
57 C-type lectin receptor signaling pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
58 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
59 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
60 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
61 Calcium signaling pathway 💬
 2件: EDNRA, EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
62 Calcium signaling pathway 💬
 2件: EDNRA, EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
63 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
64 cAMP signaling pathway 💬
 1件: EDNRA 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
65 cAMP signaling pathway 💬
 1件: EDNRA 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
66 Cell adhesion molecules 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
67 Cell adhesion molecules 💬
 1件: PDCD1 💬 Nivolumab 💬 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
68 Cellular senescence 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
69 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
70 cGMP-PKG signaling pathway 💬
 2件: EDNRA, EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
71 cGMP-PKG signaling pathway 💬
 2件: EDNRA, EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
72 cGMP-PKG signaling pathway 💬
 1件: OPRD1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
73 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
74 Chagas disease 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
75 Chagas disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
76 Chagas disease 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
77 Chagas disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
78 Chagas disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
79 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
80 Chemical carcinogenesis - receptor activation 💬
 1件: VDR 💬 Alfacalcidol 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
81 Chemokine signaling pathway 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
82 Cholinergic synapse 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
83 Coronavirus disease - COVID-19 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
84 Coronavirus disease - COVID-19 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
85 Coronavirus disease - COVID-19 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
86 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
87 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
88 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
89 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
90 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
91 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
92 Cytokine-cytokine receptor interaction 💬
 1件: CSF2RA 💬 Mavrilimumab 💬 Mavrilimumab 2件: 41, 46 💬
93 Cytokine-cytokine receptor interaction 💬
 1件: CSF3R 💬 Filgrastim 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
94 Cytokine-cytokine receptor interaction 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
95 Cytokine-cytokine receptor interaction 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
96 Cytokine-cytokine receptor interaction 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
97 Cytokine-cytokine receptor interaction 💬
 2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
98 Cytokine-cytokine receptor interaction 💬
 1件: IL23A 💬 Guselkumab 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
99 Cytokine-cytokine receptor interaction 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
100 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
101 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
102 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
103 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
104 Cytosolic DNA-sensing pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
105 Cytosolic DNA-sensing pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
106 Dilated cardiomyopathy 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
107 Dilated cardiomyopathy 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
108 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
109 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
110 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
111 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
112 EGFR tyrosine kinase inhibitor resistance 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
113 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
114 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: VDR 💬 Alfacalcidol 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
115 Epstein-Barr virus infection 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
116 Epstein-Barr virus infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
117 Epstein-Barr virus infection 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
118 Epstein-Barr virus infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
119 Epstein-Barr virus infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
120 Estrogen signaling pathway 💬
 1件: OPRM1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
121 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
122 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
123 Fluid shear stress and atherosclerosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
124 Fluid shear stress and atherosclerosis 💬
 2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
125 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
126 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
127 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
128 FoxO signaling pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
129 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
130 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
131 Graft-versus-host disease 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
132 Graft-versus-host disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
133 Graft-versus-host disease 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
134 Graft-versus-host disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
135 Graft-versus-host disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
136 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
137 Hematopoietic cell lineage 💬
 1件: CSF2RA 💬 Mavrilimumab 💬 Mavrilimumab 2件: 41, 46 💬
138 Hematopoietic cell lineage 💬
 1件: CSF3R 💬 Filgrastim 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
139 Hematopoietic cell lineage 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
140 Hematopoietic cell lineage 💬
 2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
141 Hematopoietic cell lineage 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
142 Hematopoietic cell lineage 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
143 Hematopoietic cell lineage 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
144 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 Rituximab 💬 Rituximab 48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
145 Hematopoietic cell lineage 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
146 Hematopoietic cell lineage 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
147 Hepatitis B 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
148 Hepatitis B 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
149 Hepatitis B 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
150 Hepatitis B 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
151 Hepatitis B 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
152 Hepatitis C 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
153 Hepatitis C 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
154 Hepatitis C 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
155 Hepatitis C 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
156 Herpes simplex virus 1 infection 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
157 Herpes simplex virus 1 infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
158 Herpes simplex virus 1 infection 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
159 Herpes simplex virus 1 infection 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
160 Herpes simplex virus 1 infection 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
161 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
162 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
163 HIF-1 signaling pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
164 HIF-1 signaling pathway 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
165 HIF-1 signaling pathway 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
166 Human cytomegalovirus infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
167 Human cytomegalovirus infection 💬
 1件: IL1R1 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
168 Human cytomegalovirus infection 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
169 Human cytomegalovirus infection 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
170 Human cytomegalovirus infection 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
171 Human cytomegalovirus infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
172 Human cytomegalovirus infection 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
173 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
174 Human cytomegalovirus infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
175 Human cytomegalovirus infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
176 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
177 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
178 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
179 Human papillomavirus infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
180 Human papillomavirus infection 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
181 Human papillomavirus infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
182 Human papillomavirus infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
183 Human T-cell leukemia virus 1 infection 💬
 1件: FDPS 💬 Alendronic acid 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
184 Human T-cell leukemia virus 1 infection 💬
 2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
185 Human T-cell leukemia virus 1 infection 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
186 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
187 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
188 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
189 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
190 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
191 Hypertrophic cardiomyopathy 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
192 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
193 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
194 IL-17 signaling pathway 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
195 IL-17 signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
196 IL-17 signaling pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
197 IL-17 signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
198 IL-17 signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
199 Inflammatory bowel disease 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
200 Inflammatory bowel disease 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
201 Inflammatory bowel disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
202 Inflammatory bowel disease 💬
 1件: IL23A 💬 Guselkumab 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
203 Inflammatory bowel disease 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
204 Inflammatory bowel disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
205 Inflammatory bowel disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
206 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
207 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1R1 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
208 Influenza A 💬
 1件: FDPS 💬 Alendronic acid 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
209 Influenza A 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
210 Influenza A 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
211 Influenza A 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
212 Influenza A 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
213 Influenza A 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
214 Influenza A 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
215 Influenza A 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
216 Insulin resistance 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
217 Insulin resistance 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
218 Insulin resistance 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
219 Intestinal immune network for IgA production 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
220 Intestinal immune network for IgA production 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
221 JAK-STAT signaling pathway 💬
 1件: CSF2RA 💬 Mavrilimumab 💬 Mavrilimumab 2件: 41, 46 💬
222 JAK-STAT signaling pathway 💬
 1件: CSF3R 💬 Filgrastim 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
223 JAK-STAT signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
224 JAK-STAT signaling pathway 💬
 1件: IL23A 💬 Guselkumab 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
225 JAK-STAT signaling pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
226 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
227 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
228 JAK-STAT signaling pathway 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
229 JAK-STAT signaling pathway 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
230 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
231 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
232 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
233 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
234 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
235 Legionellosis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
236 Legionellosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
237 Legionellosis 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
238 Legionellosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
239 Legionellosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
240 Leishmaniasis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
241 Leishmaniasis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
242 Leishmaniasis 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
243 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
244 Leishmaniasis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
245 Leishmaniasis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
246 Lipid and atherosclerosis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
247 Lipid and atherosclerosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
248 Lipid and atherosclerosis 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
249 Lipid and atherosclerosis 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
250 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
251 Lipid and atherosclerosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
252 Lipid and atherosclerosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
253 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
254 Malaria 💬
 1件: IL12A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
255 Malaria 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
256 Malaria 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
257 Malaria 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
258 Malaria 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
259 MAPK signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
260 MAPK signaling pathway 💬
 1件: IL1R1 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
261 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
262 MAPK signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
263 MAPK signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
264 Measles 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
265 Measles 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
266 Measles 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
267 Measles 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
268 Measles 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
269 Melanogenesis 💬
 1件: EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
270 Melanogenesis 💬
 1件: EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
271 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
272 Metabolic pathways 💬
 1件: FDPS 💬 Alendronic acid 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
273 Mineral absorption 💬
 1件: VDR 💬 Alfacalcidol 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
274 Morphine addiction 💬
 1件: OPRM1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
275 mTOR signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
276 mTOR signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
277 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
278 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
279 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
280 Necroptosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
281 Necroptosis 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
282 Necroptosis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
283 Necroptosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
284 Necroptosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
285 Neuroactive ligand-receptor interaction 💬
 2件: EDNRA, EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
286 Neuroactive ligand-receptor interaction 💬
 2件: EDNRA, EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
287 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Hydrocortisone 💬 Hydrocortisone 10件:  6 , 41, 46, 53, 75, 78, 81, 83, 97, 299 💬
288 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Methylprednisolone 💬 Methylprednisolone 46件:  2 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
289 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Prednisolone 💬 Prednisolone 42件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
290 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Prednisone 💬 Prednisone 45件:  2 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 💬
291 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Prednisone acetate 💬 Prednisone acetate 6件: 35, 41, 46, 49, 162, 224 💬
292 Neuroactive ligand-receptor interaction 💬
 3件: OPRD1, OPRK1, OPRM1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
293 NF-kappa B signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
294 NF-kappa B signaling pathway 💬
 1件: IL1R1 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
295 NF-kappa B signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
296 NF-kappa B signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
297 NOD-like receptor signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
298 NOD-like receptor signaling pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
299 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
300 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
301 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
302 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
303 Non-alcoholic fatty liver disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
304 Non-alcoholic fatty liver disease 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
305 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
306 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
307 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
308 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
309 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
310 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
311 Osteoclast differentiation 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
312 Osteoclast differentiation 💬
 1件: IL1R1 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
313 Osteoclast differentiation 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
314 Osteoclast differentiation 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
315 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
316 Osteoclast differentiation 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
317 Osteoclast differentiation 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
318 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
319 Pancreatic cancer 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
320 Pancreatic cancer 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
321 Parathyroid hormone synthesis, secretion and action 💬
 1件: VDR 💬 Alfacalcidol 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
322 Pathogenic Escherichia coli infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
323 Pathogenic Escherichia coli infection 💬
 1件: IL1R1 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
324 Pathogenic Escherichia coli infection 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
325 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
326 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
327 Pathways in cancer 💬
 1件: CSF2RA 💬 Mavrilimumab 💬 Mavrilimumab 2件: 41, 46 💬
328 Pathways in cancer 💬
 1件: CSF3R 💬 Filgrastim 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
329 Pathways in cancer 💬
 2件: EDNRA, EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
330 Pathways in cancer 💬
 2件: EDNRA, EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
331 Pathways in cancer 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
332 Pathways in cancer 💬
 1件: IL23A 💬 Guselkumab 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
333 Pathways in cancer 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
334 Pathways in cancer 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
335 Pathways in cancer 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
336 Pathways in cancer 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
337 Pathways in cancer 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
338 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
339 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
340 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
341 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
342 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
343 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
344 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
345 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: PDCD1 💬 Nivolumab 💬 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
346 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
347 Pertussis 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
348 Pertussis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
349 Pertussis 💬
 1件: IL23A 💬 Guselkumab 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
350 Pertussis 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
351 Pertussis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
352 Pertussis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
353 PI3K-Akt signaling pathway 💬
 1件: CSF3R 💬 Filgrastim 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
354 PI3K-Akt signaling pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
355 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
356 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
357 PI3K-Akt signaling pathway 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
358 PI3K-Akt signaling pathway 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
359 Prion disease 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
360 Prion disease 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
361 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
362 Prion disease 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
363 Prion disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
364 Prolactin signaling pathway 💬
 1件: JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
365 Prostate cancer 💬
 1件: IL1R2 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
366 Proteoglycans in cancer 💬
 1件: IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
367 Proteoglycans in cancer 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
368 Proteoglycans in cancer 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
369 Relaxin signaling pathway 💬
 1件: EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
370 Relaxin signaling pathway 💬
 1件: EDNRB 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
371 Renin secretion 💬
 1件: EDNRA 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
372 Renin secretion 💬
 1件: EDNRA 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
373 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
374 Rheumatoid arthritis 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
375 Rheumatoid arthritis 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
376 Rheumatoid arthritis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
377 Rheumatoid arthritis 💬
 1件: IL23A 💬 Guselkumab 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
378 Rheumatoid arthritis 💬
 1件: IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
379 Rheumatoid arthritis 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
380 Rheumatoid arthritis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
381 Rheumatoid arthritis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
382 RIG-I-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
383 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
384 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
385 Salmonella infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
386 Salmonella infection 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
387 Salmonella infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
388 Salmonella infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
389 Shigellosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
390 Shigellosis 💬
 1件: IL1R1 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
391 Shigellosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
392 Shigellosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
393 Signaling pathways regulating pluripotency of stem cells 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
394 Signaling pathways regulating pluripotency of stem cells 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
395 Sphingolipid signaling pathway 💬
 1件: OPRD1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
396 Sphingolipid signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
397 Sphingolipid signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
398 Systemic lupus erythematosus 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
399 Systemic lupus erythematosus 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
400 Systemic lupus erythematosus 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
401 T cell receptor signaling pathway 💬
 1件: PDCD1 💬 Nivolumab 💬 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
402 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
403 T cell receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
404 T cell receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
405 Terpenoid backbone biosynthesis 💬
 1件: FDPS 💬 Alendronic acid 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
406 TGF-beta signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
407 TGF-beta signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
408 Th1 and Th2 cell differentiation 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
409 Th1 and Th2 cell differentiation 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
410 Th1 and Th2 cell differentiation 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
411 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
412 Th17 cell differentiation 💬
 1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
413 Th17 cell differentiation 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
414 Th17 cell differentiation 💬
 1件: IL1R1 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
415 Th17 cell differentiation 💬
 1件: IL23A 💬 Guselkumab 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
416 Th17 cell differentiation 💬
 1件: IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
417 Th17 cell differentiation 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
418 Th17 cell differentiation 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
419 Th17 cell differentiation 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
420 Th17 cell differentiation 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
421 Th17 cell differentiation 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
422 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
423 TNF signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
424 TNF signaling pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
425 TNF signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
426 TNF signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
427 Toll-like receptor signaling pathway 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
428 Toll-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
429 Toll-like receptor signaling pathway 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
430 Toll-like receptor signaling pathway 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
431 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
432 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
433 Toxoplasmosis 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
434 Toxoplasmosis 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
435 Toxoplasmosis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
436 Toxoplasmosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
437 Toxoplasmosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
438 Transcriptional misregulation in cancer 💬
 1件: CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
439 Transcriptional misregulation in cancer 💬
 1件: IL1R2 💬 Anakinra 💬 Anakinra 18件:  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
440 Transcriptional misregulation in cancer 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
441 Tuberculosis 💬
 3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
442 Tuberculosis 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
443 Tuberculosis 💬
 1件: IL23A 💬 Guselkumab 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
444 Tuberculosis 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
445 Tuberculosis 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
446 Tuberculosis 💬
 2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
447 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
448 Tuberculosis 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
449 Tuberculosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
450 Tuberculosis 💬
 1件: VDR 💬 Alfacalcidol 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
451 Type I diabetes mellitus 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
452 Type I diabetes mellitus 💬
 2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
453 Type I diabetes mellitus 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
454 Type I diabetes mellitus 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
455 Type I diabetes mellitus 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
456 Type II diabetes mellitus 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
457 Type II diabetes mellitus 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
458 Vascular smooth muscle contraction 💬
 1件: EDNRA 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
459 Vascular smooth muscle contraction 💬
 1件: EDNRA 💬 Bosentan 💬 Bosentan 10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
460 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
461 Viral carcinogenesis 💬
 1件: JAK1 💬 Baricitinib 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
462 Viral carcinogenesis 💬
 1件: JAK1 💬 Upadacitinib 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
463 Viral myocarditis 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
464 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
465 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 Sarilumab 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
466 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
467 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
468 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
469 Virion - Adenovirus 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
470 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 Cyclosporine 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
471 Yersinia infection 💬
 1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
472 Yersinia infection 💬
 1件: IL6 💬 Sirukumab 💬 Sirukumab 2件: 41, 46 💬
473 Yersinia infection 💬
 1件: TNF 💬 Adalimumab 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
474 Yersinia infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬

先頭へ